Posted by Michael Wonder on 05 Apr 2023
MHRA grants ADvantage Therapeutics Innovative Licensing and Access Pathway designation for novel lead product AD04 for Phase 2b trial in Alzheimer’s sisease
5 April 2023 - ADvantage Therapeutics today announced that the MHRA has granted the Company’s lead compound AD04 an Innovation Passport for the treatment of Alzheimer's disease under the Innovative Licensing and Access Pathway.
ADvantage Therapeutics is developing AD04 as a novel immunotherapy for mild Alzheimer’s disease. The compound has been used as an adjuvant in human and animal vaccination programs.
